32 results on '"Dye, John M."'
Search Results
2. Crimean-Congo hemorrhagic fever survivors elicit protective non-neutralizing antibodies that target 11 overlapping regions on glycoprotein GP38
- Author
-
Shin, Olivia S., Monticelli, Stephanie R., Hjorth, Christy K., Hornet, Vladlena, Doyle, Michael, Abelson, Dafna, Kuehne, Ana I., Wang, Albert, Bakken, Russell R., Mishra, Akaash K., Middlecamp, Marissa, Champney, Elizabeth, Stuart, Lauran, Maurer, Daniel P., Li, Jiannan, Berrigan, Jacob, Barajas, Jennifer, Balinandi, Stephen, Lutwama, Julius J., Lobel, Leslie, Zeitlin, Larry, Walker, Laura M., Dye, John M., Chandran, Kartik, Herbert, Andrew S., Pauli, Noel T., and McLellan, Jason S.
- Abstract
Crimean-Congo hemorrhagic fever virus can cause lethal disease in humans yet there are no approved medical countermeasures. Viral glycoprotein GP38, exclusive to Nairoviridae, is a target of protective antibodies and is a key antigen in preclinical vaccine candidates. Here, we isolate 188 GP38-specific antibodies from human survivors of infection. Competition experiments show that these antibodies bind across 5 distinct antigenic sites, encompassing 11 overlapping regions. Additionally, we show structures of GP38 bound with 9 of these antibodies targeting different antigenic sites. Although these GP38-specific antibodies are non-neutralizing, several display protective efficacy equal to or better than murine antibody 13G8 in two highly stringent rodent models of infection. Together, these data expand our understanding regarding this important viral protein and may inform the development of broadly effective CCHFV antibody therapeutics.
- Published
- 2024
- Full Text
- View/download PDF
3. Toll-like receptor 4 mediates blood-brain barrier permeability and disease in C3H mice during Venezuelan equine encephalitis virus infection
- Author
-
Hollidge, Bradley S., Cohen, Courtney A., Akuoku Frimpong, Justice, Badger, Catherine V., Dye, John M., and Schmaljohn, Connie S.
- Abstract
ABSTRACTVenezuelan equine encephalitis virus (VEEV) is an encephalitic alphavirus that can cause debilitating, acute febrile illness and potentially result in encephalitis. Currently, there are no FDA-licensed vaccines or specific therapeutics for VEEV. Previous studies have demonstrated that VEEV infection results in increased blood-brain barrier (BBB) permeability that is mediated by matrix metalloproteinases (MMPs). Furthermore, after subarachnoid hemorrhage in mice, MMP-9 is upregulated in the brain and mediates BBB permeability in a toll-like receptor 4 (TLR4)-dependent manner. Here, we demonstrate that disease in C3H mice during VEEV TC-83 infection is dependent on TLR4 because intranasal infection of C3H/HeN (TLR4WT) mice with VEEV TC-83 resulted in mortality as opposed to survival of TLR4-defective C3H/HeJ (TLR4mut) mice. In addition, BBB permeability was induced to a lesser extent in TLR4mutmice compared with TLR4WTmice during VEEV TC-83 infection as determined by sodium fluorescein and fluorescently-conjugated dextran extravasation. Moreover, MMP-9, MMP-2, ICAM-1, CCL2 and IFN-γ were all induced to significantly lower levels in the brains of infected TLR4mutmice compared with infected TLR4WTmice despite the absence of significantly different viral titers or immune cell populations in the brains of infected TLR4WTand TLR4mutmice. These data demonstrate the critical role of TLR4 in mediating BBB permeability and disease in C3H mice during VEEV TC-83 infection, which suggests that TLR4 is a potential target for the development of therapeutics for VEEV.
- Published
- 2021
- Full Text
- View/download PDF
4. A novel compound active against SARS-CoV-2 targeting uridylate-specific endoribonuclease (NendoU/NSP15): in silicoand in vitroinvestigationsElectronic supplementary information (ESI) available. See DOI: 10.1039/d1md00202c
- Author
-
Kumar, Sumit, Gupta, Yash, Zak, Samantha E., Upadhyay, Charu, Sharma, Neha, Herbert, Andrew S., Durvasula, Ravi, Potemkin, Vladimir, Dye, John M., Poonam, Kempaiah, Prakasha, and Rathi, Brijesh
- Abstract
NendoU (NSP15) is an Mn(2+)-dependent, uridylate-specific enzyme, which leaves 2′-3′-cyclic phosphates 5′ to the cleaved bond. Our in-house library was subjected to high throughput virtual screening (HTVS) to identify compounds with potential to inhibit NendoU enzyme, high-rank compounds (those that bound to multiple target structures) were further subjected to 100 nanoseconds MD simulations. Among these, one was found to be bound highly stable within the active site of the NendoU protein structure. Here, we are reporting a derivative of piperazine based ‘(2S,3S)-3-amino-1-(4-(4-(tert-butyl)benzyl)piperazin-1-yl)-4-phenylbutan-2-ol’ (IV) from our in-house libraries having potential efficacy against SARS-CoV-2 in in vitro assays. This compound demonstrated inhibition of viral replication at the same level as Ivermectin, a known SARS-CoV-2 inhibitor, which is not used due to its toxicity at a higher than the currently approved dosage. Compound IVwas not toxic to the cell lines up to a 50 μM concentration and exhibited IC50sof 4.97 μM and 8.46 μM in viral entry and spread assay, respectively. Therefore, this novel class of NendoU inhibitor could provide new insights for the development of treatment options for COVID-19.
- Published
- 2021
- Full Text
- View/download PDF
5. Synthesis and Structure–Activity Relationships of 3,5-Disubstituted-pyrrolo[2,3‑b]pyridines as Inhibitors of Adaptor-Associated Kinase 1 with Antiviral Activity.
- Author
-
Verdonck, Sven, Pu, Szu-Yuan, Sorrell, Fiona J., Elkins, Jon M., Froeyen, Mathy, Gao, Ling-Jie, Prugar, Laura I., Dorosky, Danielle E., Brannan, Jennifer M., Barouch-Bentov, Rina, Knapp, Stefan, Dye, John M., Herdewijn, Piet, Einav, Shirit, and De Jonghe, Steven
- Published
- 2019
- Full Text
- View/download PDF
6. Optimization of Isothiazolo[4,3‑b]-pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity.
- Author
-
Pu, Szu-Yuan, Wouters, Randy, Schor, Stanford, Rozenski, Jef, Barouch-Bentov, Rina, Prugar, Laura I., O'Brien, Cecilia M., Brannan, Jennifer M., Dye, John M., Herdewijn, Piet, De Jonghe, Steven, and Einav, Shirit
- Published
- 2018
- Full Text
- View/download PDF
7. Synthesis and Structure–Activity Relationships of 3,5-Disubstituted-pyrrolo[2,3-b]pyridines as Inhibitors of Adaptor-Associated Kinase 1 with Antiviral Activity
- Author
-
Verdonck, Sven, Pu, Szu-Yuan, Sorrell, Fiona J., Elkins, Jon M., Froeyen, Mathy, Gao, Ling-Jie, Prugar, Laura I., Dorosky, Danielle E., Brannan, Jennifer M., Barouch-Bentov, Rina, Knapp, Stefan, Dye, John M., Herdewijn, Piet, Einav, Shirit, and De Jonghe, Steven
- Abstract
There are currently no approved drugs for the treatment of emerging viral infections, such as dengue and Ebola. Adaptor-associated kinase 1 (AAK1) is a cellular serine–threonine protein kinase that functions as a key regulator of the clathrin-associated host adaptor proteins and regulates the intracellular trafficking of multiple unrelated RNA viruses. Moreover, AAK1 is overexpressed specifically in dengue virus-infected but not bystander cells. Because AAK1 is a promising antiviral drug target, we have embarked on an optimization campaign of a previously identified 7-azaindole analogue, yielding novel pyrrolo[2,3-b]pyridines with high AAK1 affinity. The optimized compounds demonstrate improved activity against dengue virus both in vitro and in human primary dendritic cells and the unrelated Ebola virus. These findings demonstrate that targeting cellular AAK1 may represent a promising broad-spectrum antiviral strategy.
- Published
- 2019
- Full Text
- View/download PDF
8. Structural basis of broad ebolavirus neutralization by a human survivor antibody
- Author
-
West, Brandyn R., Wec, Anna Z., Moyer, Crystal L., Fusco, Marnie L., Ilinykh, Philipp A., Huang, Kai, Wirchnianski, Ariel S., James, Rebekah M., Herbert, Andrew S., Hui, Sean, Goodwin, Eileen, Howell, Katie A., Kailasan, Shweta, Aman, M. Javad, Walker, Laura M., Dye, John M., Bukreyev, Alexander, Chandran, Kartik, and Saphire, Erica Ollmann
- Abstract
The structural features that govern broad-spectrum activity of broadly neutralizing anti-ebolavirus antibodies (Abs) outside of the internal fusion loop epitope are currently unknown. Here we describe the structure of a broadly neutralizing human monoclonal Ab (mAb), ADI-15946, which was identified in a human survivor of the 2013–2016 outbreak. The crystal structure of ADI-15946 in complex with cleaved Ebola virus glycoprotein (EBOV GPCL) reveals that binding of the mAb structurally mimics the conserved interaction between the EBOV GP core and its glycan cap β17–β18 loop to inhibit infection. Both endosomal proteolysis of EBOV GP and binding of mAb FVM09 displace this loop, thereby increasing exposure of ADI-15946’s conserved epitope and enhancing neutralization. Our work also mapped the paratope of ADI-15946, thereby explaining reduced activity against Sudan virus, which enabled rational, structure-guided engineering to enhance binding and neutralization of Sudan virus while retaining the parental activity against EBOV and Bundibugyo virus.
- Published
- 2019
- Full Text
- View/download PDF
9. Protocadherin-1 is essential for cell entry by New World hantaviruses
- Author
-
Jangra, Rohit K., Herbert, Andrew S., Li, Rong, Jae, Lucas T., Kleinfelter, Lara M., Slough, Megan M., Barker, Sarah L., Guardado-Calvo, Pablo, Román-Sosa, Gleyder, Dieterle, M. Eugenia, Kuehne, Ana I., Muena, Nicolás A., Wirchnianski, Ariel S., Nyakatura, Elisabeth K., Fels, J. Maximilian, Ng, Melinda, Mittler, Eva, Pan, James, Bharrhan, Sushma, Wec, Anna Z., Lai, Jonathan R., Sidhu, Sachdev S., Tischler, Nicole D., Rey, Félix A., Moffat, Jason, Brummelkamp, Thijn R., Wang, Zhongde, Dye, John M., and Chandran, Kartik
- Abstract
The zoonotic transmission of hantaviruses from their rodent hosts to humans in North and South America is associated with a severe and frequently fatal respiratory disease, hantavirus pulmonary syndrome (HPS)1,2. No specific antiviral treatments for HPS are available, and no molecular determinants of in vivo susceptibility to hantavirus infection and HPS are known. Here we identify the human asthma-associated gene protocadherin-1 (PCDH1)3–6as an essential determinant of entry and infection in pulmonary endothelial cells by two hantaviruses that cause HPS, Andes virus (ANDV) and Sin Nombre virus (SNV). In vitro, we show that the surface glycoproteins of ANDV and SNV directly recognize the outermost extracellular repeat domain of PCDH1—a member of the cadherin superfamily7,8—to exploit PCDH1 for entry. In vivo, genetic ablation of PCDH1renders Syrian golden hamsters highly resistant to a usually lethal ANDV challenge. Targeting PCDH1 could provide strategies to reduce infection and disease caused by New World hantaviruses.
- Published
- 2018
- Full Text
- View/download PDF
10. Structural and mechanistic basis of neutralization by a pan-hantavirus protective antibody
- Author
-
Mittler, Eva, Serris, Alexandra, Esterman, Emma S., Florez, Catalina, Polanco, Laura C., O’Brien, Cecilia M., Slough, Megan M., Tynell, Janne, Gröning, Remigius, Sun, Yan, Abelson, Dafna M., Wec, Anna Z., Haslwanter, Denise, Keller, Markus, Ye, Chunyan, Bakken, Russel R., Jangra, Rohit K., Dye, John M., Ahlm, Clas, Rappazzo, C. Garrett, Ulrich, Rainer G., Zeitlin, Larry, Geoghegan, James C., Bradfute, Steven B., Sidoli, Simone, Forsell, Mattias N.E., Strandin, Tomas, Rey, Felix A., Herbert, Andrew S., Walker, Laura M., Chandran, Kartik, and Guardado-Calvo, Pablo
- Abstract
Emerging rodent-borne hantaviruses cause severe diseases in humans with no approved vaccines or therapeutics. We recently isolated a monoclonal broadly neutralizing antibody (nAb) from a Puumala virus–experienced human donor. Here, we report its structure bound to its target, the Gn/Gc glycoprotein heterodimer comprising the viral fusion complex. The structure explains the broad activity of the nAb: It recognizes conserved Gc fusion loop sequences and the main chain of variable Gn sequences, thereby straddling the Gn/Gc heterodimer and locking it in its prefusion conformation. We show that the nAb’s accelerated dissociation from the divergent Andes virus Gn/Gc at endosomal acidic pH limits its potency against this highly lethal virus and correct this liability by engineering an optimized variant that sets a benchmark as a candidate pan-hantavirus therapeutic.
- Published
- 2023
- Full Text
- View/download PDF
11. A Serological Point-of-Care Test for the Detection of IgG Antibodies against Ebola Virus in Human Survivors
- Author
-
Brangel, Polina, Sobarzo, Ariel, Parolo, Claudio, Miller, Benjamin S., Howes, Philip D., Gelkop, Sigal, Lutwama, Julius J., Dye, John M., McKendry, Rachel A., Lobel, Leslie, and Stevens, Molly M.
- Abstract
Ebola virus disease causes widespread and highly fatal epidemics in human populations. Today, there is still great need for point-of-care tests for diagnosis, patient management and surveillance, both during and post outbreaks. We present a point-of-care test comprising an immunochromatographic strip and a smartphone reader, which detects and semiquantifies Ebola-specific antibodies in human survivors. We developed a Sudan virus glycoprotein monoplex platform and validated it using sera from 90 human survivors and 31 local noninfected controls. The performance of the glycoprotein monoplex was 100% sensitivity and 98% specificity compared to standard whole antigen enzyme-linked immunosorbent assay (ELISA), and it was validated with freshly collected patient samples in Uganda. Moreover, we constructed a multiplex test for simultaneous detection of antibodies against three recombinant Sudan virus proteins. A pilot study comprising 15 survivors and 5 noninfected controls demonstrated sensitivity and specificity of 100% compared to standard ELISA. Finally, we developed a second multiplex subtype assay for the identification of exposure to three related EVD species: Sudan virus, Bundibugyo virus and Ebola virus (formerly Zaire) using recombinant viral glycoprotein. This multiplex test could distinguish between the host’s immunity to specific viral species and identify cross-reactive immunity. These developed serological platforms consisted of capture ligands with high specificity and sensitivity, in-house developed strips and a compatible smartphone application. These platforms enabled rapid and portable testing, data storage and sharing as well as geographical tagging of the tested individuals in Uganda. This platform holds great potential as a field tool for diagnosis, vaccine development, and therapeutic evaluation.
- Published
- 2018
- Full Text
- View/download PDF
12. Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses
- Author
-
Stonier, Spencer W., Herbert, Andrew S., Kuehne, Ana I., Sobarzo, Ariel, Habibulin, Polina, Dahan, Chen V. Abramovitch, James, Rebekah M., Egesa, Moses, Cose, Stephen, Lutwama, Julius Julian, Lobel, Leslie, and Dye, John M.
- Abstract
Until recently, immune responses in filovirus survivors remained poorly understood. Early studies revealed IgM and IgG responses to infection with various filoviruses, but recent outbreaks have greatly expanded our understanding of filovirus immune responses. Immune responses in survivors of Ebola virus (EBOV) and Sudan virus (SUDV) infections have provided the most insight, with T cell responses as well as detailed antibody responses having been characterized. Immune responses to Marburg virus (MARV), however, remain almost entirely uncharacterized. We report that immune responses in MARV survivors share characteristics with EBOV and SUDV infections but have some distinct differences. MARV survivors developed multivariate CD4+ T cell responses but limited CD8+ T cell responses, more in keeping with SUDV survivors than EBOV survivors. In stark contrast to SUDV survivors, rare neutralizing antibody responses in MARV survivors diminished rapidly after the outbreak. These results warrant serious consideration for any vaccine or therapeutic that seeks to be broadly protective, as different filoviruses may require different immune responses to achieve immunity.
- Published
- 2017
- Full Text
- View/download PDF
13. Generation and characterization of protective antibodies to Marburg virus
- Author
-
Froude, Jeffrey W., Pelat, Thibaut, Miethe, Sebastian, Zak, Samantha E., Wec, Anna Z., Chandran, Kartik, Brannan, Jennifer Mary, Bakken, Russell R., Hust, Michael, Thullier, Philippe, and Dye, John M.
- Abstract
ABSTRACTMarburg virus (MARV) and Ebola virus (EBOV) have been a source of epidemics and outbreaks for several decades. We present here the generation and characterization of the first protective antibodies specific for wild-type MARV. Non-human primates (NHP), cynomolgus macaques, were immunized with viral-replicon particles expressing the glycoproteins (GP) of MARV (Ci67 isolate). An antibody fragment (single-chain variable fragment, scFv) phage display library was built after four immunogen injections, and screened against the GP1-649of MARV. Sequencing of 192 selected clones identified 18 clones with distinct VHand VLsequences. Four of these recombinant antibodies (R4A1, R4B11, R4G2, and R3F6) were produced in the scFv-Fc format for in vivostudies. Mice that were challenged with wild-type Marburg virus (Ci67 isolate) receiving 100 µg of scFv-Fc on days −1, 1 and 3 demonstrated protective efficacies ranging from 75–100%. The amino-acid sequences of the scFv-Fcs are similar to those of their human germline counterparts, sharing an identity ranging between 68 and 100% to human germline immunoglobulin. These results demonstrate for the first time that recombinant antibodies offer protection against wild-type MARV, and suggest they may be promising candidates for further therapeutic development especially due to their human homology.
- Published
- 2017
- Full Text
- View/download PDF
14. Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus
- Author
-
Howell, Katie A., Brannan, Jennifer M., Bryan, Christopher, McNeal, Andrew, Davidson, Edgar, Turner, Hannah L., Vu, Hong, Shulenin, Sergey, He, Shihua, Kuehne, Ana, Herbert, Andrew S., Qiu, Xiangguo, Doranz, Benjamin J., Holtsberg, Frederick W., Ward, Andrew B., Dye, John M., and Aman, M. Javad
- Abstract
Drug combinations are synergistic when their combined efficacy exceeds the sum of the individual actions, but they rarely include ineffective drugs that become effective only in combination. We identified several “enabling pairs” of neutralizing and non-neutralizing anti-ebolavirus monoclonal antibodies, whose combination exhibited new functional profiles, including transforming a non-neutralizing antibody to a neutralizer. Sub-neutralizing concentrations of antibodies 2G4 or m8C4 enabled non-neutralizing antibody FVM09 (IC50>1 μM) to exhibit potent neutralization (IC501–10 nM). While FVM09 or m8C4 alone failed to protect Ebola-virus-infected mice, a combination of the two antibodies provided 100% protection. Furthermore, non-neutralizers FVM09 and FVM02 exponentially enhanced the potency of two neutralizing antibodies against both Ebola and Sudan viruses. We identified a hotspot for the binding of these enabling antibody pairs near the interface of the glycan cap and GP2. Enabling cooperativity may be an underappreciated phenomenon for viruses, with implications for the design and development of immunotherapeutics and vaccines.
- Published
- 2017
- Full Text
- View/download PDF
15. Detection of biomarkers for filoviral infection with a silicon photonic resonator platform
- Author
-
Meserve, Krista, Qavi, Abraham J., Aman, M. Javad, Vu, Hong, Zeitlin, Larry, Dye, John M., Froude, Jeffrey W., Leung, Daisy W., Yang, Lan, Holtsberg, Frederick W., Amarasinghe, Gaya K., and Bailey, Ryan C.
- Abstract
This protocol describes the use of silicon photonic microring resonator sensors for detection of Ebola virus (EBOV) and Sudan virus (SUDV) soluble glycoprotein (sGP). This protocol encompasses biosensor functionalization of silicon microring resonator chips, detection of protein biomarkers in sera, preparing calibration standards for analytical validation, and quantification of the results from these experiments. This protocol is readily adaptable toward other analytes, including cytokines, chemokines, nucleic acids, and viruses.
- Published
- 2022
- Full Text
- View/download PDF
16. Human Survivors of Disease Outbreaks Caused by Ebola or Marburg Virus Exhibit Cross-Reactive and Long-Lived Antibody Responses
- Author
-
Natesan, Mohan, Jensen, Stig M., Keasey, Sarah L., Kamata, Teddy, Kuehne, Ana I., Stonier, Spencer W., Lutwama, Julius Julian, Lobel, Leslie, Dye, John M., and Ulrich, Robert G.
- Abstract
ABSTRACTA detailed understanding of serological immune responses to Ebola and Marburg virus infections will facilitate the development of effective diagnostic methods, therapeutics, and vaccines. We examined antibodies from Ebola or Marburg survivors 1 to 14 years after recovery from disease, by using a microarray that displayed recombinant nucleoprotein (NP), viral protein 40 (VP40), envelope glycoprotein (GP), and inactivated whole virions from six species of filoviruses. All three outbreak cohorts exhibited significant antibody responses to antigens from the original infecting species and a pattern of additional filoviruses that varied by outbreak. NP was the most cross-reactive antigen, while GP was the most specific. Antibodies from survivors of infections by Marburg marburgvirus(MARV) species were least cross-reactive, while those from survivors of infections by Sudan virus(SUDV) species exhibited the highest cross-reactivity. Based on results revealed by the protein microarray, persistent levels of antibodies to GP, NP, and VP40 were maintained for up to 14 years after infection, and survival of infection caused by one species imparted cross-reactive antibody responses to other filoviruses.
- Published
- 2016
- Full Text
- View/download PDF
17. Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site
- Author
-
Howell, Katie A., Qiu, Xiangguo, Brannan, Jennifer M., Bryan, Christopher, Davidson, Edgar, Holtsberg, Frederick W., Wec, Anna Z., Shulenin, Sergey, Biggins, Julia E., Douglas, Robin, Enterlein, Sven G., Turner, Hannah L., Pallesen, Jesper, Murin, Charles D., He, Shihua, Kroeker, Andrea, Vu, Hong, Herbert, Andrew S., Fusco, Marnie L., Nyakatura, Elisabeth K., Lai, Jonathan R., Keck, Zhen-Yong, Foung, Steven K.H., Saphire, Erica Ollmann, Zeitlin, Larry, Ward, Andrew B., Chandran, Kartik, Doranz, Benjamin J., Kobinger, Gary P., Dye, John M., and Aman, M. Javad
- Abstract
Previous efforts to identify cross-neutralizing antibodies to the receptor-binding site (RBS) of ebolavirus glycoproteins have been unsuccessful, largely because the RBS is occluded on the viral surface. We report a monoclonal antibody (FVM04) that targets a uniquely exposed epitope within the RBS; cross-neutralizes Ebola (EBOV), Sudan (SUDV), and, to a lesser extent, Bundibugyo viruses; and shows protection against EBOV and SUDV in mice and guinea pigs. The antibody cocktail ZMapp™ is remarkably effective against EBOV (Zaire) but does not cross-neutralize other ebolaviruses. By replacing one of the ZMapp™ components with FVM04, we retained the anti-EBOV efficacy while extending the breadth of protection to SUDV, thereby generating a cross-protective antibody cocktail. In addition, we report several mutations at the base of the ebolavirus glycoprotein that enhance the binding of FVM04 and other cross-reactive antibodies. These findings have important implications for pan-ebolavirus vaccine development and defining broadly protective antibody cocktails.
- Published
- 2016
- Full Text
- View/download PDF
18. Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail
- Author
-
Kugelman, Jeffrey R., Kugelman-Tonos, Johanny, Ladner, Jason T., Pettit, James, Keeton, Carolyn M., Nagle, Elyse R., Garcia, Karla Y., Froude, Jeffrey W., Kuehne, Ana I., Kuhn, Jens H., Bavari, Sina, Zeitlin, Larry, Dye, John M., Olinger, Gene G., Sanchez-Lockhart, Mariano, and Palacios, Gustavo F.
- Abstract
MB-003, a plant-derived monoclonal antibody cocktail used effectively in treatment of Ebola virus infection in non-human primates, was unable to protect two of six animals when initiated 1 or 2 days post-infection. We characterized a mechanism of viral escape in one of the animals, after observation of two clusters of genomic mutations that resulted in five nonsynonymous mutations in the monoclonal antibody target sites. These mutations were linked to a reduction in antibody binding and later confirmed to be present in a viral isolate that was not neutralized in vitro. Retrospective evaluation of a second independent study allowed the identification of a similar case. Four SNPs in previously identified positions were found in this second fatality, suggesting that genetic drift could be a potential cause for treatment failure. These findings highlight the importance selecting different target domains for each component of the cocktail to minimize the potential for viral escape.
- Published
- 2015
- Full Text
- View/download PDF
19. Rapid detection of an Ebola biomarker with optical microring resonators
- Author
-
Qavi, Abraham J., Meserve, Krista, Aman, M. Javad, Vu, Hong, Zeitlin, Larry, Dye, John M., Froude, Jeffrey W., Leung, Daisy W., Yang, Lan, Holtsberg, Frederick W., Bailey, Ryan C., and Amarasinghe, Gaya K.
- Abstract
Ebola virus (EBOV) is a highly infectious pathogen, with a case mortality rate as high as 89%. Rapid therapeutic treatments and supportive measures can drastically improve patient outcome; however, the symptoms of EBOV disease (EVD) lack specificity from other endemic diseases. Given the high mortality and significant symptom overlap, there is a critical need for sensitive, rapid diagnostics for EVD. Facile diagnosis of EVD remains a challenge. Here, we describe a rapid and sensitive diagnostic for EVD through microring resonator sensors in conjunction with a unique biomarker of EBOV infection, soluble glycoprotein (sGP). Microring resonator sensors detected sGP in under 40 min with a limit of detection (LOD) as low as 1.00 ng/mL in serum. Furthermore, we validated our assay with the detection of sGP in serum from EBOV-infected non-human primates. Our results demonstrate the utility of a high-sensitivity diagnostic platform for detection of sGP for diagnosis of EVD.
- Published
- 2022
- Full Text
- View/download PDF
20. Synthetic Antibodies with a Human Framework That Protect Mice from Lethal Sudan Ebolavirus Challenge
- Author
-
Chen, Gang, Koellhoffer, Jayne F., Zak, Samantha E., Frei, Julia C., Liu, Nina, Long, Hua, Ye, Wei, Nagar, Kaajal, Pan, Guohua, Chandran, Kartik, Dye, John M., Sidhu, Sachdev S., and Lai, Jonathan R.
- Abstract
The ebolaviruses cause severe and rapidly progressing hemorrhagic fever. There are five ebolavirus species; although much is known about Zaire ebolavirus (EBOV) and its neutralization by antibodies, little is known about Sudan ebolavirus (SUDV), which is emerging with increasing frequency. Here we describe monoclonal antibodies containing a human framework that potently inhibit infection by SUDV and protect mice from lethal challenge. The murine antibody 16F6, which binds the SUDV envelope glycoprotein (GP), served as the starting point for design. Sequence and structural alignment revealed similarities between 16F6 and YADS1, a synthetic antibody with a humanized scaffold. A focused phage library was constructed and screened to impart 16F6-like recognition properties onto the YADS1 scaffold. A panel of 17 antibodies were characterized and found to have a range of neutralization potentials against a pseudotype virus infection model. Neutralization correlated with GP binding as determined by ELISA. Two of these clones, E10 and F4, potently inhibited authentic SUDV and conferred protection and memory immunity in mice from lethal SUDV challenge. E10 and F4 were further shown to bind to the same epitope on GP as 16F6 with comparable affinities. These antibodies represent strong immunotherapeutic candidates for treatment of SUDV infection.
- Published
- 2014
- Full Text
- View/download PDF
21. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
- Author
-
Westendorf, Kathryn, Žentelis, Stefanie, Wang, Lingshu, Foster, Denisa, Vaillancourt, Peter, Wiggin, Matthew, Lovett, Erica, van der Lee, Robin, Hendle, Jörg, Pustilnik, Anna, Sauder, J. Michael, Kraft, Lucas, Hwang, Yuri, Siegel, Robert W., Chen, Jinbiao, Heinz, Beverly A., Higgs, Richard E., Kallewaard, Nicole L., Jepson, Kevin, Goya, Rodrigo, Smith, Maia A., Collins, David W., Pellacani, Davide, Xiang, Ping, de Puyraimond, Valentine, Ricicova, Marketa, Devorkin, Lindsay, Pritchard, Caitlin, O’Neill, Aoise, Dalal, Kush, Panwar, Pankaj, Dhupar, Harveer, Garces, Fabian A., Cohen, Courtney A., Dye, John M., Huie, Kathleen E., Badger, Catherine V., Kobasa, Darwyn, Audet, Jonathan, Freitas, Joshua J., Hassanali, Saleema, Hughes, Ina, Munoz, Luis, Palma, Holly C., Ramamurthy, Bharathi, Cross, Robert W., Geisbert, Thomas W., Menachery, Vineet, Lokugamage, Kumari, Borisevich, Viktoriya, Lanz, Iliana, Anderson, Lisa, Sipahimalani, Payal, Corbett, Kizzmekia S., Yang, Eun Sung, Zhang, Yi, Shi, Wei, Zhou, Tongqing, Choe, Misook, Misasi, John, Kwong, Peter D., Sullivan, Nancy J., Graham, Barney S., Fernandez, Tara L., Hansen, Carl L., Falconer, Ester, Mascola, John R., Jones, Bryan E., and Barnhart, Bryan C.
- Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 (COVID-19) when administered early. However, SARS-CoV-2 variants of concern (VOCs) have negatively affected therapeutic use of some authorized mAbs. Using a high-throughput B cell screening pipeline, we isolated LY-CoV1404 (bebtelovimab), a highly potent SARS-CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody. LY-CoV1404 potently neutralizes authentic SARS-CoV-2, B.1.1.7, B.1.351, and B.1.617.2. In pseudovirus neutralization studies, LY-CoV1404 potently neutralizes variants, including B.1.1.7, B.1.351, B.1.617.2, B.1.427/B.1.429, P.1, B.1.526, B.1.1.529, and the BA.2 subvariant. Structural analysis reveals that the contact residues of the LY-CoV1404 epitope are highly conserved, except for N439 and N501. The binding and neutralizing activity of LY-CoV1404 is unaffected by the most common mutations at these positions (N439K and N501Y). The broad and potent neutralization activity and the relatively conserved epitope suggest that LY-CoV1404 has the potential to be an effective therapeutic agent to treat all known variants.
- Published
- 2022
- Full Text
- View/download PDF
22. Human antibody recognizing a quaternary epitope in the Puumala virus glycoprotein provides broad protection against orthohantaviruses
- Author
-
Mittler, Eva, Wec, Anna Z., Tynell, Janne, Guardado-Calvo, Pablo, Wigren-Byström, Julia, Polanco, Laura C., O’Brien, Cecilia M., Slough, Megan M., Abelson, Dafna M., Serris, Alexandra, Sakharkar, Mrunal, Pehau-Arnaudet, Gerard, Bakken, Russell R., Geoghegan, James C., Jangra, Rohit K., Keller, Markus, Zeitlin, Larry, Vapalahti, Olli, Ulrich, Rainer G., Bornholdt, Zachary A., Ahlm, Clas, Rey, Felix A., Dye, John M., Bradfute, Steven B., Strandin, Tomas, Herbert, Andrew S., Forsell, Mattias N. E., Walker, Laura M., and Chandran, Kartik
- Abstract
The rodent-borne hantavirus Puumala virus (PUUV) and related agents cause hemorrhagic fever with renal syndrome (HFRS) in humans. Other hantaviruses, including Andes virus (ANDV) and Sin Nombre virus, cause a distinct zoonotic disease, hantavirus cardiopulmonary syndrome (HCPS). Although these infections are severe and have substantial case fatality rates, no FDA-approved hantavirus countermeasures are available. Recent work suggests that monoclonal antibodies may have therapeutic utility. We describe here the isolation of human neutralizing antibodies (nAbs) against tetrameric Gn/Gc glycoprotein spikes from PUUV-experienced donors. We define a dominant class of nAbs recognizing the “capping loop” of Gn that masks the hydrophobic fusion loops in Gc. A subset of nAbs in this class, including ADI-42898, bound Gn/Gc complexes but not Gn alone, strongly suggesting that they recognize a quaternary epitope encompassing both Gn and Gc. ADI-42898 blocked the cell entry of seven HCPS- and HFRS-associated hantaviruses, and single doses of this nAb could protect Syrian hamsters and bank voles challenged with the highly virulent HCPS-causing ANDV and HFRS-causing PUUV, respectively. ADI-42898 is a promising candidate for clinical development as a countermeasure for both HCPS and HFRS, and its mode of Gn/Gc recognition informs the development of broadly protective hantavirus vaccines.
- Published
- 2022
- Full Text
- View/download PDF
23. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
- Author
-
Loo, Yueh-Ming, McTamney, Patrick M., Arends, Rosalinda H., Abram, Michael E., Aksyuk, Anastasia A., Diallo, Seme, Flores, Daniel J., Kelly, Elizabeth J., Ren, Kuishu, Roque, Richard, Rosenthal, Kim, Streicher, Katie, Tuffy, Kevin M., Bond, Nicholas J., Cornwell, Owen, Bouquet, Jerome, Cheng, Lily I., Dunyak, James, Huang, Yue, Rosenbaum, Anton I., Pilla Reddy, Venkatesh, Andersen, Hanne, Carnahan, Robert H., Crowe, James E., Kuehne, Ana I., Herbert, Andrew S., Dye, John M., Bright, Helen, Kallewaard, Nicole L., Pangalos, Menelas N., and Esser, Mark T.
- Abstract
Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, there remains a need for more prevention and treatment options for individuals remaining at risk of coronavirus disease 2019 (COVID-19). Monoclonal antibodies (mAbs) against the viral spike protein have potential to both prevent and treat COVID-19 and reduce the risk of severe disease and death. Here, we describe AZD7442, a combination of two mAbs, AZD8895 (tixagevimab) and AZD1061 (cilgavimab), that simultaneously bind to distinct, nonoverlapping epitopes on the spike protein receptor binding domain to neutralize SARS-CoV-2. Initially isolated from individuals with prior SARS-CoV-2 infection, the two mAbs were designed to extend their half-lives and reduce effector functions. The AZD7442 mAbs individually prevent the spike protein from binding to angiotensin-converting enzyme 2 receptor, blocking virus cell entry, and neutralize all tested SARS-CoV-2 variants of concern. In a nonhuman primate model of SARS-CoV-2 infection, prophylactic AZD7442 administration prevented infection, whereas therapeutic administration accelerated virus clearance from the lung. In an ongoing phase 1 study in healthy participants (NCT04507256), a 300-mg intramuscular injection of AZD7442 provided SARS-CoV-2 serum geometric mean neutralizing titers greater than 10-fold above those of convalescent serum for at least 3 months, which remained threefold above those of convalescent serum at 9 months after AZD7442 administration. About 1 to 2% of serum AZD7442 was detected in nasal mucosa, a site of SARS-CoV-2 infection. Extrapolation of the time course of serum AZD7442 concentration suggests AZD7442 may provide up to 12 months of protection and benefit individuals at high-risk of COVID-19.
- Published
- 2022
- Full Text
- View/download PDF
24. How to turn competitors into collaborators
- Author
-
Saphire, Erica Ollmann, Dye, John M., Kobinger, Gary P., Zeitlin, Larry, Chandran, Kartik, and Garry, Robert F.
- Published
- 2017
- Full Text
- View/download PDF
25. Profiling the Native Specific Human Humoral Immune Response to Sudan Ebola Virus Strain Gulu by Chemiluminescence Enzyme-Linked Immunosorbent Assay
- Author
-
Sobarzo, Ariel, Perelman, Eddie, Groseth, Allison, Dolnik, Olga, Becker, Stephan, Lutwama, Julius Julian, Dye, John M., Yavelsky, Victoria, Lobel, Leslie, and Marks, Robert S.
- Abstract
ABSTRACTEbolavirus, a member of the family Filoviridae, causes high lethality in humans and nonhuman primates. Research focused on protection and therapy for Ebola virus infection has investigated the potential role of antibodies. Recent evidence suggests that antibodies can be effective in protection from lethal challenge with Ebola virus in nonhuman primates. However, despite these encouraging results, studies have not yet determined the optimal antibodies and composition of an antibody cocktail, if required, which might serve as a highly effective and efficient prophylactic. To better understand optimal antibodies and their targets, which might be important for protection from Ebola virus infection, we sought to determine the profile of viral protein-specific antibodies generated during a natural cycle of infection in humans. To this end, we characterized the profile of antibodies against individual viral proteins of Sudan Ebola virus (Gulu) in human survivors and nonsurvivors of the outbreak in Gulu, Uganda, in 2000-2001. We developed a unique chemiluminescence enzyme-linked immunosorbent assay (ELISA) for this purpose based on the full-length recombinant viral proteins NP, VP30, and VP40 and two recombinant forms of the viral glycoprotein (GP1-294and GP1-649) of Sudan Ebola virus (Gulu). Screening results revealed that the greatest immunoreactivity was directed to the viral proteins NP and GP1-649, followed by VP40. Comparison of positive immunoreactivity between the viral proteins NP, GP1-649, and VP40 demonstrated a high correlation of immunoreactivity between these viral proteins, which is also linked with survival. Overall, our studies of the profile of immunorecognition of antibodies against four viral proteins of Sudan Ebola virus in human survivors may facilitate development of effective monoclonal antibody cocktails in the future.
- Published
- 2012
- Full Text
- View/download PDF
26. Filovirius vaccines
- Author
-
Bradfute, Steven B., Dye, John M., and Bavari, Sina
- Abstract
Filoviruses can cause severe and often fatal hemorrhagic fever in humans and non-human primates (NHPs). Although there are currently no clinically proven treatments for filovirus disease, much progress has been made in recent years in the discovery of therapeutics and vaccines against these viruses. A variety of vaccine platforms have been shown to be effective against filovirus infection. This review summarizes the literature in this field, focusing on vaccines that have been shown to protect NHPs from infection. Furthermore, the uses of rodent models in vaccine development, as well as correlates of immunity, are discussed.
- Published
- 2011
- Full Text
- View/download PDF
27. Protection of Nonhuman Primates against Two Species of Ebola Virus Infection with a Single Complex Adenovirus Vector
- Author
-
Pratt, William D., Wang, Danher, Nichols, Donald K., Luo, Min, Woraratanadharm, Jan, Dye, John M., Holman, David H., and Dong, John Y.
- Abstract
ABSTRACTEbola viruses are highly pathogenic viruses that cause outbreaks of hemorrhagic fever in humans and other primates. To meet the need for a vaccine against the several types of Ebola viruses that cause human diseases, we developed a multivalent vaccine candidate (EBO7) that expresses the glycoproteins of Zaire ebolavirus(ZEBOV) and Sudan ebolavirus(SEBOV) in a single complex adenovirus-based vector (CAdVax). We evaluated our vaccine in nonhuman primates against the parenteral and aerosol routes of lethal challenge. EBO7 vaccine provided protection against both Ebola viruses by either route of infection. Significantly, protection against SEBOV given as an aerosol challenge, which has not previously been shown, could be achieved with a boosting vaccination. These results demonstrate the feasibility of creating a robust, multivalent Ebola virus vaccine that would be effective in the event of a natural virus outbreak or biological threat.
- Published
- 2010
- Full Text
- View/download PDF
28. A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition.
- Author
-
Dieterle, M. Eugenia, Haslwanter, Denise, Bortz III, Robert H., Wirchnianski, Ariel S., Lasso, Gorka, Vergnolle, Olivia, Abbasi, Shawn A., Fels, J. Maximilian, Laudermilch, Ethan, Florez, Catalina, Mengotto, Amanda, Kimmel, Duncan, Malonis, Ryan J., Georgiev, George, Quiroz, Jose, Barnhill, Jason, Pirofski, Liise-anne, Daily, Johanna P., Dye, John M., and Lai, Jonathan R.
- Abstract
There is an urgent need for vaccines and therapeutics to prevent and treat COVID-19. Rapid SARS-CoV-2 countermeasure development is contingent on the availability of robust, scalable, and readily deployable surrogate viral assays to screen antiviral humoral responses, define correlates of immune protection, and down-select candidate antivirals. Here, we generate a highly infectious recombinant vesicular stomatitis virus (VSV) bearing the SARS-CoV-2 spike glycoprotein S as its sole entry glycoprotein and show that this recombinant virus, rVSV-SARS-CoV-2 S, closely resembles SARS-CoV-2 in its entry-related properties. The neutralizing activities of a large panel of COVID-19 convalescent sera can be assessed in a high-throughput fluorescent reporter assay with rVSV-SARS-CoV-2 S, and neutralization of rVSV-SARS-CoV-2 S and authentic SARS-CoV-2 by spike-specific antibodies in these antisera is highly correlated. Our findings underscore the utility of rVSV-SARS-CoV-2 S for the development of spike-specific therapeutics and for mechanistic studies of viral entry and its inhibition. • Highly infectious recombinant VSV expressing SARS-CoV-2 spike (S) was generated • rVSV-SARS-CoV-2 S resembles SARS-CoV-2 in entry and inhibitor or antibody sensitivity • rVSV-SARS-CoV-2 S affords rapid screens and forward-genetic analyses of antivirals Surrogate systems are needed to evaluate COVID-19 vaccines and therapeutics rapidly and at scale. Dieterle & Haslwanter et al. describe a highly infectious recombinant vesicular stomatitis virus encoding the SARS-CoV-2 spike protein that is suitable for screening and mechanistic studies of small molecule inhibitors, recombinant biologics, and convalescent plasma. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
29. Persistent Marburg Virus Infection in the Testes of Nonhuman Primate Survivors.
- Author
-
Coffin, Kayla M., Liu, Jun, Warren, Travis K., Blancett, Candace D., Kuehl, Kathleen A., Nichols, Donald K., Bearss, Jeremy J., Schellhase, Christopher W., Retterer, Cary J., Weidner, Jessica M., Radoshitzky, Sheli R., Brannan, Jennifer M., Cardile, Anthony P., Dye, John M., Palacios, Gustavo, Sun, Mei G., Kuhn, Jens H., Bavari, Sina, and Zeng, Xiankun
- Abstract
Summary Sexual transmission of filoviruses was first reported in 1968 after an outbreak of Marburg virus (MARV) disease and recently caused flare-ups of Ebola virus disease in the 2013–2016 outbreak. How filoviruses establish testicular persistence and are shed in semen remain unknown. We discovered that persistent MARV infection of seminiferous tubules, an immune-privileged site that harbors sperm production, is a relatively common event in crab-eating macaques that survived infection after antiviral treatment. Persistence triggers severe testicular damage, including spermatogenic cell depletion and inflammatory cell invasion. MARV mainly persists in Sertoli cells, leading to breakdown of the blood-testis barrier formed by inter-Sertoli cell tight junctions. This disruption is accompanied by local infiltration of immunosuppressive CD4
+ Foxp3+ regulatory T cells. Our study elucidates cellular events associated with testicular persistence that may promote sexual transmission of filoviruses and suggests that targeting immunosuppression may be warranted to clear filovirus persistence in damaged immune-privileged sites. Graphical Abstract Highlights • Marburg virus (MARV) persists in the testes of macaque survivors after treatment • MARV infiltrates macaque testes late in infection • MARV persists in testicular Sertoli cells, thereby disrupting tissue barrier integrity • Local immunosuppressive Treg cell infiltration may sustain persistent infection Sexual filovirus transmission causes outbreak flare-ups. Coffin et al. address the cellular events accompanying testicular Marburg virus persistence in macaque survivors. The virus persists in the immune-privileged Sertoli cells of the seminiferous tubules, which results in loss of barrier integrity and immune privilege, allowing infiltration of immunosuppressive Treg cells. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
30. Longitudinal peripheral blood transcriptional analysis of a patient with severe Ebola virus disease
- Author
-
Kash, John C., Walters, Kathie-Anne, Kindrachuk, Jason, Baxter, David, Scherler, Kelsey, Janosko, Krisztina B., Adams, Rick D., Herbert, Andrew S., James, Rebekah M., Stonier, Spencer W., Memoli, Matthew J., Dye, John M., Davey, Richard T., Chertow, Daniel S., and Taubenberger, Jeffery K.
- Abstract
Transcriptomic analysis of leukocytes from a severe Ebola virus disease patient revealed transitions driven by viral clearance, coagulopathy, and multiorgan dysfunction.
- Published
- 2017
- Full Text
- View/download PDF
31. Haploid Genetic Screen Reveals a Profound and Direct Dependence on Cholesterol for Hantavirus Membrane Fusion
- Author
-
Kleinfelter, Lara M., Jangra, Rohit K., Jae, Lucas T., Herbert, Andrew S., Mittler, Eva, Stiles, Katie M., Wirchnianski, Ariel S., Kielian, Margaret, Brummelkamp, Thijn R., Dye, John M., and Chandran, Kartik
- Abstract
ABSTRACTHantaviruses cause hemorrhagic fever with renal syndrome (HFRS) in the Old World and a highly fatal hantavirus cardiopulmonary syndrome (HCPS) in the New World. No vaccines or antiviral therapies are currently available to prevent or treat hantavirus disease, and gaps in our understanding of how hantaviruses enter cells challenge the search for therapeutics. We performed a haploid genetic screen in human cells to identify host factors required for entry by Andes virus, a highly virulent New World hantavirus. We found that multiple genes involved in cholesterol sensing, regulation, and biosynthesis, including key components of the sterol response element-binding protein (SREBP) pathway, are critical for Andes virus entry. Genetic or pharmacological disruption of the membrane-bound transcription factor peptidase/site-1 protease (MBTPS1/S1P), an SREBP control element, dramatically reduced infection by virulent hantaviruses of both the Old World and New World clades but not by rhabdoviruses or alphaviruses, indicating that this pathway is broadly, but selectively, required by hantaviruses. These results could be fully explained as arising from the modest depletion of cellular membrane cholesterol that accompanied S1P disruption. Mechanistic studies of cells and with protein-free liposomes suggested that high levels of cholesterol are specifically needed for hantavirus membrane fusion. Taken together, our results indicate that the profound dependence on target membrane cholesterol is a fundamental, and unusual, biophysical property of hantavirus glycoprotein-membrane interactions during entry.IMPORTANCEAlthough hantaviruses cause important human diseases worldwide, no specific antiviral treatments are available. One of the major obstacles to the development of new therapies is a lack of understanding of how hantaviruses hijack our own host factors to enter cells. Here, we identified multiple cellular genes that control the levels of cholesterol in cellular membranes to be important for hantavirus entry. Our findings suggest that high concentrations of cholesterol in cellular membranes are required at a specific step in the entry process—fusion between viral and cellular membranes—that allows escape of the hantavirus genome into the host cell cytoplasm to initiate infection. Our findings uncover a fundamental feature of the hantavirus infection mechanism and point to cholesterol-lowering drugs as a potential new treatment of hantaviral infections.
- Published
- 2015
- Full Text
- View/download PDF
32. Niemann-Pick C1 Is Essential for Ebolavirus Replication and Pathogenesis In Vivo
- Author
-
Herbert, Andrew S., Davidson, Cristin, Kuehne, Ana I., Bakken, Russell, Braigen, Stephen Z., Gunn, Kathryn E., Whelan, Sean P., Brummelkamp, Thijn R., Twenhafel, Nancy A., Chandran, Kartik, Walkley, Steven U., and Dye, John M.
- Abstract
ABSTRACTRecent work demonstrated that the Niemann-Pick C1 (NPC1) protein is an essential entry receptor for filoviruses. While previous studies focused on filovirus entry requirements of NPC1 in vitro, its roles in filovirus replication and pathogenesis in vivoremain unclear. Here, we evaluated the importance of NPC1, and its partner in cholesterol transport, NPC2, by using a mouse model of Ebolavirus (EBOV) disease. We found that, whereas wild-type mice had high viral loads and succumbed to EBOV infection, Npc1−/−mice were entirely free of viral replication and completely protected from EBOV disease. Interestingly, Npc1+/−mice transiently developed high levels of viremia, but were nevertheless substantially protected from EBOV challenge. We also found Npc2−/−mice to be fully susceptible to EBOV infection, while Npc1−/−mice treated to deplete stored lysosomal cholesterol remained completely resistant to EBOV infection. These results provide mechanistic evidence that NPC1 is directly required for EBOV infection in vivo, with little or no role for NPC1/NPC2-dependent cholesterol transport. Finally, we assessed the in vivoantiviral efficacies of three compounds known to inhibit NPC1 function or NPC1-glycoprotein binding in vitro. Two compounds reduced viral titers in vivoand provided a modest, albeit not statistically significant, degree of protection. Taken together, our results show that NPC1 is critical for replication and pathogenesis in animals and is a bona fide target for development of antifilovirus therapeutics. Additionally, our findings with Npc1+/−mice raise the possibility that individuals heterozygous for NPC1 may have a survival advantage in the face of EBOV infection.IMPORTANCEResearchers have been searching for an essential filovirus receptor for decades, and numerous candidate receptors have been proposed. However, none of the proposed candidate receptors has proven essential in all in vitroscenarios, nor have they proven essential when evaluated using animal models. In this report, we provide the first example of a knockout mouse that is completely refractory to EBOV infection, replication, and disease. The findings detailed here provide the first critical in vivodata illustrating the absolute requirement of NPC1 for filovirus infection in mice. Our work establishes NPC1 as a legitimate target for the development of anti-EBOV therapeutics. However, the limited success of available NPC1 inhibitors to protect mice from EBOV challenge highlights the need for new molecules or approaches to target NPC1 in vivo.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.